ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Theralase Technologies Inc (QB)

Theralase Technologies Inc (QB) (TLTFF)

0,1715
0,0008
(0,47%)
Geschlossen 12 Juni 10:00PM

Theralase Technologies Inc (QB) (TLTFF) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
0,1715
( 0,47% )
Gebot
0,0001
Fragen
800,20
Volumen
271.833
0,1644 Tagesbereich 0,1771
0,1019 52-Wochen-Bereich 0,3061
Marktkapitalisierung
Handelsende
0,1707
Handelsbeginn
0,1644
Letzte Trade
1000
@
0.1715
Letzter Handelszeitpunkt
Finanzvolumen
US$ 46.689
VWAP
0,171755
Durchschnittliches Volumen (3 Mio.)
US$ 334.007
Ausgegebene Aktien
295.671.318
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-16,09
Gewinn pro Aktie (EPS)
-0,01
Erlöse (LTM)
857,91k
Nettogewinn (LTM)
-3,68M

Über Theralase Technologies Inc (QB)

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Divisio... Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada. Mehr anzeigen

Sektor
Healthcare
Branche
Medical Equipment & Supplies
Hauptsitz
Toronto, Canada
Gegründet
-
Theralase Technologies Inc (QB) is listed in the Healthcare sector of the OTC Markets with ticker TLTFF. The last closing price for Theralase Technologies (QB) was US$0,17. Over the last year, Theralase Technologies (QB) shares have traded in a share price range of US$ 0,1019 to US$ 0,3061.

Theralase Technologies (QB) currently has 295.671.318 shares in issue. The market capitalisation of Theralase Technologies (QB) is US$50,71 million. Theralase Technologies (QB) has a price to earnings ratio (PE ratio) of -16.09.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.00150.8823529411760.170.18490.1627728980.17114567CS
4-0.0285-14.250.20.20.14852330770.16931481CS
12-0.0489-22.18693284940.22040.30610.14851936280.19206653CS
260.059352.85204991090.11220.30610.10521452790.19192964CS
520.045235.78780680920.12630.30610.10191038420.17549536CS
156-0.0285-14.250.20.30610.08786760.16699815CS
260-0.0595-25.75757575760.2310.380.08876610.20103486CS

TLTFF - Frequently Asked Questions (FAQ)

What is the current Theralase Technologies Inc (QB) share price?
The current share price of Theralase Technologies Inc (QB) is US$ 0,1715
How many Theralase Technologies Inc (QB) shares are in issue?
Theralase Technologies Inc (QB) has 295.671.318 shares in issue
What is the market cap of Theralase Technologies Inc (QB)?
The market capitalisation of Theralase Technologies Inc (QB) is USD 50,71M
What is the 1 year trading range for Theralase Technologies Inc (QB) share price?
Theralase Technologies Inc (QB) has traded in the range of US$ 0,1019 to US$ 0,3061 during the past year
What is the PE ratio of Theralase Technologies Inc (QB)?
The price to earnings ratio of Theralase Technologies Inc (QB) is -16,09
What is the cash to sales ratio of Theralase Technologies Inc (QB)?
The cash to sales ratio of Theralase Technologies Inc (QB) is 79,27
What is the registered address of Theralase Technologies Inc (QB)?
The registered address for Theralase Technologies Inc (QB) is 41 Hollinger Road, Toronto, Ontario, M4B 3G4
What is the Theralase Technologies Inc (QB) website address?
The website address for Theralase Technologies Inc (QB) is www.theralase.com
Which industry sector does Theralase Technologies Inc (QB) operate in?
Theralase Technologies Inc (QB) operates in the Medical Equipment & Supplies sector

TLTFF Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen